梯瓦计划裁员约8%，跨国药企如何在风暴中重塑增长？

Group 1: Company Strategy and Financial Performance - Teva aims to transform into a biopharmaceutical company, targeting approximately $700 million in net savings by 2027 while offsetting the profit loss from the generic version of Revlimid and achieving a 30% operating profit margin [2] - The company reported a revenue of $3.9 billion in Q1 2025, a 5% increase year-over-year, with innovative products contributing significantly to this growth [7][8] - Teva's U.S. revenue reached $1.91 billion in Q1 2025, a 10.72% increase, with a profit of $532 million, reflecting a 52% year-over-year growth [8] Group 2: Cost-Cutting Measures - Teva plans to reduce general and administrative expenses by 100 basis points through the use of business centers, AI, and digital tools [2] - The company intends to lay off approximately 8% of its workforce, affecting around 2,400 employees, marking the largest reduction in three years [9] - Teva is also looking to consolidate suppliers to cut spending by about 10% [2] Group 3: Market Challenges and Industry Trends - The global pharmaceutical industry is experiencing a downturn, prompting many companies, including Teva, to implement cost control measures to maintain operations and R&D investments [5][11] - The industry faces challenges such as patent expirations and increased competition from generics, leading companies to adjust their R&D pipelines and focus on higher return products [13][14] - Teva's strategic shift is part of a broader trend among multinational pharmaceutical companies to optimize operations and adapt to a complex market environment [6][11]